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Abstract  
Objectives: Circulating placental growth factor (P lGF) is a potential biomarker for 
preeclampsia. Prior studies show its limited precision in predicting or diagnosing 
preeclampsia, underscoring a common problem in biomarker data analyses in general - that 
large studies are needed to overcome clinical heterogeneity and to provide sufficient 
statistical power. Attaining such sample sizes often requires aggregation of cohorts. Different 
studies may use disparate platforms for laboratory analyses, complicating data merging.  
Here, we assessed whether PlGF concentrations could be merged across studies using inter-
platform standardization. 
Methods: Of 16516 pregnancies from 23 cohorts, 12804 had at least one PlGF concentration 
(gestational age >20 weeks), analysed using one of four platforms: R&D Systems, Alere-
Triage, Roche-Elecsys or Abbott-Architect. Two merging algorithms, using Z-Score or 
Multiple of Median (MOM) transformations, were applied. A single Best Reference Curve 
(BRC), based on merged non-case PlGF concentrations, was constructed. Case-identification 
performance of the BRC for PlGF was compared to platform-specific curves.  
Results: PlGF concentrations from different analytical platforms were merged (Z-scores 
marginally better than MOMs) and, overall, BRC case-identification rates out-performed 
platform-specific curves.  
Conclusion: Laboratory measurements from different platforms can be standardised and 
merged to give reference curves from aggregated PlGF datasets. This method allows for 
analysis of PlGF as a diagnostic marker for preeclampsia and is generalisable to other 
medical questions, thereby extending the scope of individual studies to answer a variety of 
important medical questions. 
